CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the stocks that could 10x over the next 10 years. Piper Sandler boosted its ...

CRISPR Cas9 gene therapy explained with DNA scissors, hereditary diseases treatment, and designer babies ethical dilemmas ...

Any molecular biologist will tell you that genetic engineering is tricky. But up until recently we might be witnessing a new ...

Scientists at Rothamsted Research have successfully developed wheat with dramatically reduced levels of asparagine, without ...

A US patent board last week backed the Broad Institute’s claim to CRISPR use in human and animal cells, not the Nobel winners ...

In back-to-back studies published in Nature, researchers from Purdue University and Columbia University report a naturally ...

Samarth Kulkarni is one of the most consequential figures in modern biotechnology, widely recognised for his role in transforming CRISPR Therapeutics from an early-stage gene-editing company into the ...

Trace the timeline of CRISPR-Cas9 from its 2012 discovery to the latest AI-driven advancements and "N-of-1" clinical ...

Detailed price information for Editas Medicine (EDIT-Q) from The Globe and Mail including charting and trades.

Most people who have heard of clustered regularly interspaced short palindromic repeats (more commonly known as CRISPR) associate it with gene editing—the precise molecular scissors that allow ...

A U.S. Patent Office tribunal has ruled against Nobel Prize-winning scientists Jennifer Doudna and Emmanuelle Charpentier for ...

If you are wondering whether CRISPR Therapeutics at around US$48.75 is a bargain or a concern, the key question is how its current share price lines up with what the business may be worth. The stock ...